Molecular Diagnostics Market Set To Grow To $11bn By 2021

14 August 2018
Pharma

Visiongain has launched a new pharma report The Molecular Diagnostics (MDx) Market Forecast 2017-2027: Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing

Molecular diagnostics is a fast-growing and rapidly evolving sector of the IVD market, made possible by the growing understanding of the human genome. Molecular diagnostics tests have also led to the emerging field of companion diagnostics, in which a MDx test is used to identify whether a specific therapy is likely to be effective for an individual patient. The market for MDx is growing rapidly due to increasing biomarker discover and adoption rates, but its growth is limited by several regulatory and reimbursement issues.

The lead analyst of the report commented “There will be increasing adoption of molecular diagnostics over the forecast period as the benefits of increasing accuracy and speed of diagnosis become increasingly apparent. Another driver for the MDx industry will be the advent of Point-Of-Care MDx testing, which will greatly increase the potential availability of molecular testing as it moves out of high and moderate complexity laboratories into primary care settings such as hospitals and physicians’ offices.

The advent of personalised healthcare is also being driven by molecular diagnostics, as the ability to better stratify patients with added genetic information will allow physicians to select treatments that have a higher chance of success in an individual patient, as well as allowing for more detailed monitoring and evaluation of disease progression”

Leading companies featured in the report include Roche Diagnostics, Qiagen, Hologic, bioMérieux, Agilent Technologies, Becton, Dickinson & Company,

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever